The U.S. Food and Drug Administration issued a statement, they have no indication of an association between fractures of the femur and oral bisphosphonates – found a type of drug to treat osteoporosis, claims despite the claims otherwise.

According to several reports show an increase in the surface of subtrochanteric femoral fractures atypical women prescribed oral bisphosphonates, the FDA began to investigate drugs for osteoporosis. The fractures occurred just below the hip in the thigh – the largest bone in the human body – an unusual place to enter for a break, after which the investigation.

Bisphosphonates are a type of drug used for osteoporosis

offset the bone loss and prevent fractures in women during menopause. The following medicines are popular oral bisphosphonates:

* Fosamax – Merck and Co />
* Reclast – Novartis AG
* Actonel – Warner Chilcott

The FDA has requested information from manufacturers of oral bisphosphonates in June 2008, but did not find Rick elevated in women with drugs. Despite the obvious connection between the two, the FDA is working with external sources in order to examine the matter further.

bisphosphonates have a controversial history. In 2008, drugs were investigated according to several reports, they linked to an increased risk of cardiovascular complications, although the FDA has since been an indication, not a comprehensive cardiac risk are issued.> Merck is facing about 900 lawsuits claim Fosamax patients permanent damage pine. A federal judge refused to dismiss a complaint in January 2010, Fosamax, which means that the drug was responsible for damages, claiming the lower jaw in a woman in Indiana, the drug for about eight years, took a break.

The manufacturer, Merck, has repeatedly denied any association between Fosamax and ONJ or increased risk of fracture. Ron Rogers, a spokesman for Merck, said that “was linked to clinical trials, Fosamax, with an increased risk of fracture of the skeleton.” Until generic versions was available, Fosamax generated around billion dollars in sales for the company.

Unless stated otherwise, by their doctor, the FDA recommends that patients continue taking their medication. The FDA notified healthcare professionals aware of its potential “possible” atypical trochanteric femoral fractures in patients taking oral bisphosphonates, although action has not yet been decided at this time.


Drugs to treat osteoporosis